Pimozide in autistic children

M. Ernst, H. J. Magee, N. M. Gonzalez, J. J. Locascio, C. R. Rosenberg, M. Campbell

Research output: Contribution to journalArticle

Abstract

This open pilot study explored the efficacy and safety of pimozide, over a 3-week period, in hospitalized autistic children. Eight males, ages 4.2 to 8.3 years, completed the study. Intellectual functioning ranged from moderate to profound mental retardation. Symptoms included severe withdrawal, stereotypies, hyperactivity and/or hypoactivity, aggressiveness, and temper tantrums. Therapeutic daily doses of pimozide ranged from 3.0 mg to 6.0 mg with a mean of 4.9 mg (0.12-0.32 mg/kg; mean, 0.22). Laboratory studies including electrocardiogram and liver function tests remained within normal limits. Untoward effects were minimal and transient. Decreases of behavioral symptoms were evidenced on all measures including the Children's Psychiatric Rating Scale, Clinical Global Impressions, and Global Clinical Judgments Scale (consensus rating). Of the 5 hypoactive children, 4 showed a decrease in hypoactivity, whereas 1 child showed worsening. These findings are promising and indicate the need for further study.

Original languageEnglish (US)
Pages (from-to)187-192
Number of pages6
JournalPsychopharmacology Bulletin
Volume28
Issue number2
StatePublished - 1992
Externally publishedYes

Fingerprint

Pimozide
Child Psychiatry
Behavioral Symptoms
Hospitalized Child
Liver Function Tests
Intellectual Disability
Consensus
Electrocardiography
Safety
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology

Cite this

Ernst, M., Magee, H. J., Gonzalez, N. M., Locascio, J. J., Rosenberg, C. R., & Campbell, M. (1992). Pimozide in autistic children. Psychopharmacology Bulletin, 28(2), 187-192.

Pimozide in autistic children. / Ernst, M.; Magee, H. J.; Gonzalez, N. M.; Locascio, J. J.; Rosenberg, C. R.; Campbell, M.

In: Psychopharmacology Bulletin, Vol. 28, No. 2, 1992, p. 187-192.

Research output: Contribution to journalArticle

Ernst, M, Magee, HJ, Gonzalez, NM, Locascio, JJ, Rosenberg, CR & Campbell, M 1992, 'Pimozide in autistic children', Psychopharmacology Bulletin, vol. 28, no. 2, pp. 187-192.
Ernst M, Magee HJ, Gonzalez NM, Locascio JJ, Rosenberg CR, Campbell M. Pimozide in autistic children. Psychopharmacology Bulletin. 1992;28(2):187-192.
Ernst, M. ; Magee, H. J. ; Gonzalez, N. M. ; Locascio, J. J. ; Rosenberg, C. R. ; Campbell, M. / Pimozide in autistic children. In: Psychopharmacology Bulletin. 1992 ; Vol. 28, No. 2. pp. 187-192.
@article{a1797b7b06e54f62baa3ca9d59f1b37e,
title = "Pimozide in autistic children",
abstract = "This open pilot study explored the efficacy and safety of pimozide, over a 3-week period, in hospitalized autistic children. Eight males, ages 4.2 to 8.3 years, completed the study. Intellectual functioning ranged from moderate to profound mental retardation. Symptoms included severe withdrawal, stereotypies, hyperactivity and/or hypoactivity, aggressiveness, and temper tantrums. Therapeutic daily doses of pimozide ranged from 3.0 mg to 6.0 mg with a mean of 4.9 mg (0.12-0.32 mg/kg; mean, 0.22). Laboratory studies including electrocardiogram and liver function tests remained within normal limits. Untoward effects were minimal and transient. Decreases of behavioral symptoms were evidenced on all measures including the Children's Psychiatric Rating Scale, Clinical Global Impressions, and Global Clinical Judgments Scale (consensus rating). Of the 5 hypoactive children, 4 showed a decrease in hypoactivity, whereas 1 child showed worsening. These findings are promising and indicate the need for further study.",
author = "M. Ernst and Magee, {H. J.} and Gonzalez, {N. M.} and Locascio, {J. J.} and Rosenberg, {C. R.} and M. Campbell",
year = "1992",
language = "English (US)",
volume = "28",
pages = "187--192",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "2",

}

TY - JOUR

T1 - Pimozide in autistic children

AU - Ernst, M.

AU - Magee, H. J.

AU - Gonzalez, N. M.

AU - Locascio, J. J.

AU - Rosenberg, C. R.

AU - Campbell, M.

PY - 1992

Y1 - 1992

N2 - This open pilot study explored the efficacy and safety of pimozide, over a 3-week period, in hospitalized autistic children. Eight males, ages 4.2 to 8.3 years, completed the study. Intellectual functioning ranged from moderate to profound mental retardation. Symptoms included severe withdrawal, stereotypies, hyperactivity and/or hypoactivity, aggressiveness, and temper tantrums. Therapeutic daily doses of pimozide ranged from 3.0 mg to 6.0 mg with a mean of 4.9 mg (0.12-0.32 mg/kg; mean, 0.22). Laboratory studies including electrocardiogram and liver function tests remained within normal limits. Untoward effects were minimal and transient. Decreases of behavioral symptoms were evidenced on all measures including the Children's Psychiatric Rating Scale, Clinical Global Impressions, and Global Clinical Judgments Scale (consensus rating). Of the 5 hypoactive children, 4 showed a decrease in hypoactivity, whereas 1 child showed worsening. These findings are promising and indicate the need for further study.

AB - This open pilot study explored the efficacy and safety of pimozide, over a 3-week period, in hospitalized autistic children. Eight males, ages 4.2 to 8.3 years, completed the study. Intellectual functioning ranged from moderate to profound mental retardation. Symptoms included severe withdrawal, stereotypies, hyperactivity and/or hypoactivity, aggressiveness, and temper tantrums. Therapeutic daily doses of pimozide ranged from 3.0 mg to 6.0 mg with a mean of 4.9 mg (0.12-0.32 mg/kg; mean, 0.22). Laboratory studies including electrocardiogram and liver function tests remained within normal limits. Untoward effects were minimal and transient. Decreases of behavioral symptoms were evidenced on all measures including the Children's Psychiatric Rating Scale, Clinical Global Impressions, and Global Clinical Judgments Scale (consensus rating). Of the 5 hypoactive children, 4 showed a decrease in hypoactivity, whereas 1 child showed worsening. These findings are promising and indicate the need for further study.

UR - http://www.scopus.com/inward/record.url?scp=0026741577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026741577&partnerID=8YFLogxK

M3 - Article

C2 - 1513923

AN - SCOPUS:0026741577

VL - 28

SP - 187

EP - 192

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 2

ER -